2 insiders at Relmada Therapeutics, Inc. (RLMD) reported open-market stock purchases totaling $1,671,990 in recent weeks, according to filings with the U.S. Securities and Exchange Commission. The largest reported purchase came from Shenouda Maged (officer: Chief Financial Officer), who acquired 120,200 shares at $4.20 on September 09, 2026.
Source: SEC Form 4. Option grants and tax-withholding sales are excluded.
| Date | Insider | Role | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|
| 2026-09-10 | Shenouda Maged | officer: Chief Financial Officer | 79,800 | $4.25 | $339,150 | SEC Form 4 |
| 2026-09-10 | TRAVERSA SERGIO | director, officer: Chief Executive Officer | 100,000 | $4.10 | $410,000 | SEC Form 4 |
| 2026-09-09 | Shenouda Maged | officer: Chief Financial Officer | 120,200 | $4.20 | $504,840 | SEC Form 4 |
| 2026-09-09 | TRAVERSA SERGIO | director, officer: Chief Executive Officer | 100,000 | $4.18 | $418,000 | SEC Form 4 |
Relmada Therapeutics, Inc. is a Healthcare company in the Biotechnology industry. It carried a market capitalization of about $474M, with shares trading near $4.52.
This article is automated factual reporting of public SEC filings, for informational purposes only. It is not investment advice, nor a recommendation, offer or solicitation to buy or sell any security, and reflects no opinion on the company. Figures are drawn from filings believed reliable but are not guaranteed. Always verify against the primary SEC filing and consult a licensed professional. Investing can lose value, up to total loss.